US equities |
NVDA $240.68 ▲+0.75% SPCX $173.86 ▲+1.62% MU $1,066.88 ▲+0.27% MRVL $285.26 ▲+5.17% AMD $657.30 ▲+4.05% SNDK $1,669.99 ▼-2.00% INTC $114.72 ▼-1.27% AVGO $378.06 ▲+4.29%
FinancialContent

Biodesix, Inc. - Common Stock (NQ:BDSX)

28.11 -0.95 (-3.25%)
Delayed Quote Updated: 12:51 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak ↗
Via Chartmill
Biodesix (NASDAQ:BDSX) Q2 EPS Beats, Revenue In Line, Shares Slip ↗
Via Chartmill
Biodesix Inc (NASDAQ:BDSX) Q1 Results Smash Estimates, Shares Jump on Raised Guidance ↗
Via Chartmill
Biodesix Inc (NASDAQ:BDSX) Reports Q4 2025 Earnings Beat and First Adjusted EBITDA Profitability ↗
Via Chartmill
Topics Earnings
BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? ↗
Via Stocktwits
News headline image
Biodesix (BDSX) Q2 2026 Earnings Call Transcript ↗
Revenue jumped 34% as diagnostic testing surged on primary care adoption gains. 
Via The Motley Fool
Topics Earnings
News headline image
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference ↗
Biodesix (NASDAQ:BDSX) said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the... 
Via MarketBeat
News headline image
Biodesix Q2 Earnings Call Highlights ↗
Biodesix (NASDAQ:BDSX) reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its... 
Via MarketBeat
Topics Earnings
News headline image
Biodesix Announces Second Quarter 2026 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix (BDSX) Q1 2026 Earnings Transcript ↗
Biodesix (BDSX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Biodesix BDSX Q2 2025 Earnings Call Transcript ↗
Biodesix BDSX Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biodesix Announces First Quarter 2026 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Recognized as a Top Workplace for Third Consecutive Year
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix (BDSX) Q4 2025 Earnings Call Transcript ↗
Biodesix (BDSX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Biodesix, Inc.
Via GlobeNewswire
Which stocks are moving on Wednesday? ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >